Microbiome and Postbiotic Supplement Formulation Playbook: ISAPP Discipline, Identity and Stability

The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus definitions are the operational reference across regulators, scientific literature and label-claim review. Probiotic (Hill et al. 2014) — live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Three requirements: live, adequate amount delivered, demonstrated health benefit. Prebiotic (Gibson et al. 2017) — substrate selectively utilised by host microorganisms conferring a health benefit. Tightened from older 'non-digestible fermentable' definition to require host-microorganism selectivity and demonstrated benefit. Synbiotic (Swanson et al. 2020) — mixture comprising live microorganisms and substrates selectively utilised by host microorganisms conferring health benefit. Two sub-types: complementary synbiotic (separate-evidence probiotic + separate-evidence prebiotic combined) and synergistic synbiotic (defined combination demonstrating health benefit beyond either component). Postbiotic (Salminen et al. 2021) — preparation of inanimate microorganisms and/or their components conferring health benefit on the host. Notable exclusions from postbiotic definition: purified metabolites without microbial components (e.g. butyrate), purified microbial components without consensus host benefit (e.g. isolated LPS), and 'killed probiotic' marketing without measured health benefit. The discipline boundary matters because label claims and regulatory acceptance increasingly require alignment with the consensus definitions.

Strain-level identity is the regulatory expectation for probiotics across FDA, EFSA QPS (Qualified Presumption of Safety), Health Canada NHPID, Korea MFDS HFF, Japan FFC and other major frameworks. The shift from species-level (e.g. Lactobacillus rhamnosus) to strain-level (e.g. L. rhamnosus GG ATCC 53103) is driven by scientific evidence that probiotic effects are strain-specific — different strains of the same species can have markedly different safety and efficacy profiles. Whole-genome sequencing (WGS) has replaced multilocus sequence typing (MLST) and pulsed-field gel electrophoresis (PFGE) as the gold-standard identification method, with regulatory submissions and clinical-trial reporting requiring WGS-confirmed strain identity and deposit in a recognised culture collection (ATCC, DSMZ, NCIMB, JCM, KCCM, CGMCC). WGS also enables antimicrobial resistance gene screening (required under EFSA QPS and EMA guidance for probiotic safety), virulence factor screening, plasmid characterisation and biosynthetic gene cluster analysis. The 2024 update to ISO 19344 supports flow-cytometric viable cell enumeration as a complement to traditional CFU plating, with WGS-confirmed strain identity required for the reference standard. Master cell bank and working cell bank establishment with WGS verification and stability monitoring is the operational expectation for any commercial probiotic strain.

Stability discipline differs across microbiome product types. Probiotics — CFU retention through shelf life with stability-indicating viable count (ISO 19344 flow cytometry or USP <61> plate count depending on label claim format), with manufacturer overage at release (typical 50-150% of label claim depending on strain stability profile and storage condition) to ensure end-of-shelf-life label compliance; storage condition (ambient, refrigerated, frozen) and packaging (moisture barrier, oxygen barrier, desiccant) are stability-critical; freeze-dried versus spray-dried versus encapsulated formats have different stability profiles. Postbiotics — stability indicator is the bioactive component or marker (e.g. specific protein, polysaccharide, peptide or metabolite identified during health-benefit characterisation) with method-validated stability-indicating assay; cell count of the inanimate preparation is typically a secondary parameter; less environmentally sensitive than live probiotics, broader format options including ambient-stable. Prebiotics — substrate retention with chromatographic identification (e.g. HPLC for FOS, GOS, inulin, HMOs, lactulose) and stability across shelf life; generally robust to standard supplement environments; key stability concerns are moisture-driven hydrolysis and Maillard reactions in combination with reducing components. Synbiotics inherit the stability discipline of both component types. Stability protocols follow ICH Q1A long-term and accelerated conditions adapted for the matrix; market-specific stability data (e.g. zone IVb for tropical climates) may be required.

Microbiome-supplement claim substantiation requires strain-specific (probiotic), combination-specific (synbiotic) or preparation-specific (postbiotic) human evidence at the marketed dose and population, with mechanism alignment to the claimed benefit. Generic species-level evidence (e.g. broad Lactobacillus literature) does not substantiate strain-specific marketing. EFSA Article 13.5/14 health-claim authorisations for probiotics in the EU are extremely limited — no general 'probiotic' claim is authorised and EFSA has rejected the majority of submitted probiotic health-claim dossiers on grounds of insufficient evidence or characterisation, driving EU-market positioning toward structure/function statements rather than authorised health claims. US DSHEA structure/function claims and FTC substantiation are more permissive but require competent and reliable scientific evidence, FDA notification within 30 days, and Two-Step Disclaimer; UK and EU general food law restrict implied health claims even outside the Article 13 framework. Japan FFC notification and Korea MFDS HFF generic/individual pathways are receptive to strain-specific probiotic evidence with adequate dossiers. Postbiotics are an emerging regulatory category — most jurisdictions evaluate against the underlying microorganism source and the postbiotic preparation, with claim substantiation requiring preparation-specific health-benefit evidence per the ISAPP definition. Live biotherapeutic products with disease-treatment positioning fall outside supplement frameworks and require drug-pathway development.